AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. Fiorst of two parts: A phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue

Biomedicine and Pharmacotherapy

Volumn 50, Issue 5, 1996, Pages 220-227

  Mathe G ^a,b   Pontiggia, P ^b   Orbach Arbouys, S ^a   Triana, K ^a   Ambetima, N ^b   Morette, C ^a   Hallard, M ^a   Blanquet, D ^a  

^a Hopital Suisse de Paris   (France)

^b EUROPEAN HOSPITAL   (Italy)

Author keywords

3 or 4 virostatic combinations; Acriflavine; AIDS; AZT; ddC; ddI; Ellipticine; HIV 1; Virostatic rotation

Indexed keywords

ACRIFLAVINE; CD4 ANTIGEN; DIDANOSINE; ELLIPTICINE DERIVATIVE; ELLIPTINIUM; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

EID: 0029847538     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/0753-3322(96)87662-1     Document Type: Article

References (29)

1. 1 virostatics. In: Overview and Status of HIV: Course of the Disease, Prevention and/or Control. Pavia: Giornate Pavesi International Year 22, Abstract book p 10., October 1-4, 1995
2. 2 Fischl MA, Richman DD, Grieco MI. The efficacy of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV III/LAV replication in patient with AIDS or ARC: a double-blind placebo-controlled trial. N Engl J Med 1987;319:185
3. 3 Fischl MA, Richman DD, Hansen N et al. The safety and efficacy of zidovudine (AZT) in the treatment of mildly symptomatic human immuno-deficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Am Intern Med 1990;112:727
4. 4 Executive summary: dideoxyinosine/dideoxycytidine CPCRA study. In: Community Programs for Clinical Research on AIDS. Bethesda, MD: January 15, 1993
5. 5 Wainberg MA. Clinical correlated and molecular basis of HIV drug resistance. J Acquired Immune Defic Syndr 1993;6(suppl 1):S36
6. 6 Fischl M, Stanley K, Collier AC et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995;122:24
7. 7 Hammer S. Trial ACTG reported by M. VIC: un essai montre le bénéfice sur la survie d'un traitement antiviral. Quotid Med 1995;5693:10
8. 8 Cheeseman SH, Havlin D, McLaughlin MM et al. Phase I/II evaluation of neviparine alone and in combination with zidovudine for injection with immunodeficiency virus. J Acquired Immune Defic Syndr and Human Retrovirology 1995;8:141
9. 9 Mathé G, Amiel JL. Réduction de la concentration plasmatique du virus leucémigène de Charlotte Friend par immunothérapie adoptive (greffe de moelle osseuse allogénique). C R Acad Scand Paris 1964;259:4408
10. 10 Mathé G, Huppert J, Chenu E, Bourut C. Amino-acridines action on Friend's virus retrovirus in relation to their molecular ionization. Biomed Pharmacother 1989;43:235
11. 11 Mathé G, Chenu E, Bourut C et al. The in vivo effect of ellipticine analogues on the blood concentration of Friend's virus: a murine model for studying anti-HIV drugs. Biomed Pharmacother 1993;47:457
12. 12 Adriapharm. Pharmacopée Française. Xème ed. Paris: Maisonneuve, 1995:52
13. 13 Davies RH, Williams H, Smith HJ. Intermolecular forces and stereospecificity in drug action. In: Introduction to the Principle of Drugs Design. London: Wright, 1988:46
14. 14 Fosse P, René B, Le Bret M et al. Sequence requirements for mammalian topoisomerase II mediated DNA clavage stimulated by an ellipticine derivative. Nuclic Acids Res 1991;19:2861
15. 15 Kreuzer KN. DNA topoisomerases as potential targets of antiviral action. Pharmac Ther 1989;43:377
16. 16 Mathé G, Triana K. Antiviral phase 1 trial of acriflavine in HIV1 infected patients. In: Sixth International Conference on AIDS. San Francisco, 1990
17. 17 Mathé G, Pontiggia P. A screening model of anti-HIV non-AZT cross resistance virostatics. Biomed Pharmacother 1993;47:461
18. 1. Biomed Pharmacother 1996;50:(in press)
19. 19 Mathé G, Pontiggia P, Bourut C, Chenu E, Orbach-Arbouys S. In vivo eradication of Friend's virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS? Biomed Pharmacother 1994;48:51
20. 20 Razis DV, Godeau-Grynuler M, Mathé G. Medical Ethics and/or Ethical Medicine. Amsterdam: Elsevier, 1989
21. 21 Well X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117
22. 22 Mathé G. SIDA. Paris: Editions La Coutellerie, 1995
23. 23 Mathé G. Similar CD4 reduction induced by 214.5 J UV and by radiotherapy in AIDS patients. Biomed Pharmacother 1996;50:(in press)
24. 24 Ranki A, Puska P, Mattinen S et al. Effect of PUVA on immunologic and urologic fundings in HIV-infected patients. J Am Acad Dermatol 1991;24:404
25. 1 particle cure AIDS patients? Doesn't CMV activation and/or a graft-versus-host other component of the disease, also have to be controlled? I. First of two parts. Biomed Pharmacother 1996;50:this issue
26. 26 Vella S. HIV therapy advances. Update on a proteinase inhibitor. AIDS 1994;8 (suppl 3):s25
27. 27 Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV1 protease. European Australian Collaborative Ritonavir Group. N Engl J Med 1995;333:1528
28. 28 Vacca JP, Dorsey BD, Schleif WA et al. L-735, 524: an orally biovalable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci 1994;91:4096
29. 29 Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167